Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study

OBJECTIVE: This study mainly observes the efficacy and safety of almonertinib plus chemotherapy compared with almonertinib alone in the second-line treatment of advanced non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). METHODS: In this study, clinical data of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Xiaoxu, Xiang, Yan, Lu, Kaihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518400/
https://www.ncbi.nlm.nih.gov/pubmed/37752994
http://dx.doi.org/10.3389/fonc.2023.1248690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518400/
https://www.ncbi.nlm.nih.gov/pubmed/37752994
http://dx.doi.org/10.3389/fonc.2023.1248690

Ejemplares similares